Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Sep;38(9):2106–2110. doi: 10.1128/aac.38.9.2106

In vitro activities of metronidazole and its hydroxy metabolite against Bacteroides spp.

S L Pendland 1, S C Piscitelli 1, P C Schreckenberger 1, L H Danziger 1
PMCID: PMC284692  PMID: 7811027

Abstract

Metronidazole is metabolized to two major oxidative products: an acid metabolite and a hydroxy metabolite. While the activity of the acid metabolite is negligible, the activity of the hydroxy metabolite is approximately 65% of the activity of the parent drug. Pharmacokinetic studies of metronidazole and its hydroxy metabolite have shown that the MICs of both compounds remain above the MICs for most anaerobic organisms over an 8-h dosing interval. By a checkerboard assay, the combined activities of metronidazole and the hydroxy metabolite were examined against 4 quality control strains of Bacteroides species. Macrobroth tube dilutions were set up with Wilkins-Chalgren broth. Serial twofold dilutions of each agent were performed to achieve final concentrations ranging from 0.06 to 4.0 micrograms/ml. The MICs for Bacteroides fragilis and B. distasonis were 1.0 microgram/ml for both parent drug and metabolite. For B. thetaiotamicron and B. ovatus, the MICs of metronidazole and the hydroxy metabolite were 1.0 and 2.0 micrograms/ml, respectively. Synergy was determined by calculating the fractional inhibitory concentration (FIC) index. The interpretative criteria for the FIC index were as follows: synergy, FIC < or = 0.5; partial synergy, 0.51 to 0.75; indifference, FIC 0.76 to 4.0; and antagonism, FIC > 4.0. Partial synergy was observed for the four anaerobes tested, with FIC indices ranging from 0.63 to 0.75. On the basis of this data, in vitro susceptibilities to agents such as metronidazole may ultimately require reevaluation to account for active metabolites.

Full text

PDF
2106

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Betriu C., Campos E., Cabronero C., Rodriguez-Avial C., Picazo J. J. Susceptibilities of species of the Bacteroides fragilis group to 10 antimicrobial agents. Antimicrob Agents Chemother. 1990 Apr;34(4):671–673. doi: 10.1128/aac.34.4.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Collignon P. J., Munro R., Morris G. Susceptibility of anaerobic bacteria to antimicrobial agents. Pathology. 1988 Jan;20(1):48–52. doi: 10.3109/00313028809085196. [DOI] [PubMed] [Google Scholar]
  3. Cornick N. A., Cuchural G. J., Jr, Snydman D. R., Jacobus N. V., Iannini P., Hill G., Cleary T., O'Keefe J. P., Pierson C., Finegold S. M. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987. J Antimicrob Chemother. 1990 Jun;25(6):1011–1019. doi: 10.1093/jac/25.6.1011. [DOI] [PubMed] [Google Scholar]
  4. Cuchural G. J., Jr Newer beta-lactam agents and the Bacteroides fragilis group. Pharmacotherapy. 1991;11(2 ):51S–55S. [PubMed] [Google Scholar]
  5. Cuchural G. J., Jr, Tally F. P., Jacobus N. V., Aldridge K., Cleary T., Finegold S. M., Hill G., Iannini P., O'Keefe J. P., Pierson C. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother. 1988 May;32(5):717–722. doi: 10.1128/aac.32.5.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dabernat H., Delmas C., Seguy M., Fourtillan J. B., Girault J., Lareng M. B. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests. J Antimicrob Chemother. 1991 Feb;27 (Suppl A):19–30. doi: 10.1093/jac/27.suppl_a.19. [DOI] [PubMed] [Google Scholar]
  7. Earl P., Sisson P. R., Ingham H. R. Twelve-hourly dosage schedule for oral and intravenous metronidazole. J Antimicrob Chemother. 1989 Apr;23(4):619–621. doi: 10.1093/jac/23.4.619. [DOI] [PubMed] [Google Scholar]
  8. Eykyn S. J., Phillips I. Metronidazole and anaerobic sepsis. Br Med J. 1976 Dec 11;2(6049):1418–1421. doi: 10.1136/bmj.2.6049.1418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fuchs P. C., Jones R. N., Barry A. L. Evaluation of disk susceptibility testing of cefotaxime/desacetylcefotaxime. Diagn Microbiol Infect Dis. 1989 Jan-Feb;12(1):81–85. doi: 10.1016/0732-8893(89)90050-3. [DOI] [PubMed] [Google Scholar]
  10. Hall M. J., Middleton R. F., Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother. 1983 May;11(5):427–433. doi: 10.1093/jac/11.5.427. [DOI] [PubMed] [Google Scholar]
  11. Haller I. In vitro activity of the two principal oxidative metabolites of metronidazole against Bacteroides fragilis and related species. Antimicrob Agents Chemother. 1982 Jul;22(1):165–166. doi: 10.1128/aac.22.1.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hoover W. W., Barrett M. S., Jones R. N. Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin. Diagn Microbiol Infect Dis. 1992 Mar-Apr;15(3):259–266. doi: 10.1016/0732-8893(92)90122-a. [DOI] [PubMed] [Google Scholar]
  13. Jones R. N. A review of cephalosporin metabolism: a lesson to be learned for future chemotherapy. Diagn Microbiol Infect Dis. 1989 Jan-Feb;12(1):25–31. doi: 10.1016/0732-8893(89)90042-4. [DOI] [PubMed] [Google Scholar]
  14. Lau A. H., Lam N. P., Piscitelli S. C., Wilkes L., Danziger L. H. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet. 1992 Nov;23(5):328–364. doi: 10.2165/00003088-199223050-00002. [DOI] [PubMed] [Google Scholar]
  15. Li R. C., Schentag J. J., Nix D. E. The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions. Antimicrob Agents Chemother. 1993 Mar;37(3):523–531. doi: 10.1128/aac.37.3.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Loft S., Døssing M., Poulsen H. E., Sonne J., Olesen K. L., Simonsen K., Andreasen P. B. Influence of dose and route of administration on disposition of metronidazole and its major metabolites. Eur J Clin Pharmacol. 1986;30(4):467–473. doi: 10.1007/BF00607962. [DOI] [PubMed] [Google Scholar]
  17. Neu H. C. Mecillinam--an amidino penicillin which acts synergistically with other beta-lactam compounds. J Antimicrob Chemother. 1977 Jul;3 (Suppl B):43–52. doi: 10.1093/jac/3.suppl_b.43. [DOI] [PubMed] [Google Scholar]
  18. O'Keefe J. P., Troc K. A., Thompson K. D. Activity of metronidazole and its hydroxy and acid metabolites against clinical isolates of anaerobic bacteria. Antimicrob Agents Chemother. 1982 Sep;22(3):426–430. doi: 10.1128/aac.22.3.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rosenblatt J. E., Edson R. S. Symposium on antimicrobial agents. Metronidazole. Mayo Clin Proc. 1987 Nov;62(11):1013–1017. doi: 10.1016/s0025-6196(12)65074-5. [DOI] [PubMed] [Google Scholar]
  20. Sanders C. C., Sanders W. E., Jr, Moland E. S. Decimal assay for additivity of drugs permits delineation of synergy and antagonism. Antimicrob Agents Chemother. 1993 Feb;37(2):260–264. doi: 10.1128/aac.37.2.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Scully B. E. Metronidazole. Med Clin North Am. 1988 May;72(3):613–621. doi: 10.1016/s0025-7125(16)30761-1. [DOI] [PubMed] [Google Scholar]
  22. Stambaugh J. E., Feo L. G., Manthei R. W. The isolation and identification of the urinary oxidative metabolites of metronidazole in man. J Pharmacol Exp Ther. 1968 Jun;161(2):373–381. [PubMed] [Google Scholar]
  23. Stevens D. L., Bergstrom R., Gibbons A. Synergistic interaction of cefotaxime and its metabolite desacetylcefotaxime demonstrated by drug-impregnated disks. Diagn Microbiol Infect Dis. 1989 Jan-Feb;12(1):73–80. doi: 10.1016/0732-8893(89)90049-7. [DOI] [PubMed] [Google Scholar]
  24. Tally F. P., Cuchural G. J., Jr, Jacobus N. V., Gorbach S. L., Aldridge K., Cleary T., Finegold S. M., Hill G., Iannini P., O'Keefe J. P. Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States. Antimicrob Agents Chemother. 1985 Nov;28(5):675–677. doi: 10.1128/aac.28.5.675. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES